Skip to search formSkip to main contentSkip to account menu

Pyrotinib

An orally bioavailable, dual kinase inhibitor of the epidermal growth factor receptor (EGFR or HER-1) and the human epidermal growth factor receptor… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Studies on the efficacy of pyrotinib in the treatment of HER-2 positive advanced solid tumors.
e15639Background: To explore the efficacy and safety of pyrotinib in the treatment of HER-2 positive advanced solid tumors… 
2020
2020
Pyrotinib combined with capecitabine as first-line therapy for HER2-positive metastatic breast cancer: A pooled analysis of three randomized controlled trials.
e13022Background: Anti-HER2 agents combined with chemotherapy is the treatment strategy for treatment-naive HER2-positive… 
2020
2020
Concurrent ERBB2 missense mutations D769Y and D742 N Are Novel Acquired Mechanism of Gefitinib Resistance but Responds to Gefitinib plus Pyrotinib.
2020
2020
Metastatic Breast Cancer Coexisting With HER-2 Amplification and EGFR Exon 19 Deletion Benefits From EGFR-TKI Therapy: A Case Report
Background: Patients with different molecular subtypes of breast cancers have different recurrence risks and prognoses. Clinical… 
2019
2019
Pyrotinib Tops Lapatinib in Metastatic Breast Cancer.
A Chinese study of patients with HER2-positive metastatic breast cancer shows that the HER2 inhibitor pyrotinib increases… 
2019
2019
Pyrotinib Combo Moves Forward in HER2-Positive Metastatic Breast Cancer
A new combo may benefit patients with HER-2 positive metastatic breast cancer, according to a new study. 
2018
2018
Comparison the anti-tumor effect of pyrotinib, afatinb and T-DM1 in lung cancer organoids and PDX models with HER2 mutation.
e24281Background: Targeted therapy for patients of NSCLC with HER2 mutations is still on unmet need in clinical setting… 
2017
2017
Discovery and development of pyrotinib : A novel irreversible EGFR / HER 2 dual tyrosine kinase inhibitor with favorable safety pro fi les for the treatment of breast cancer
a Shanghai Hengrui Pharmaceutical Co., Ltd., 279 Wenjing Road, Shanghai 200245, China b Jiangsu Hengrui Medicine Co., Ltd… 
2016
2016
Abstract P4-14-18: Phase I study of single-agent pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with ErbB2+ metastatic breast cancer
Pyrotinib is a novel small molecule irreversible pan-ErbB receptor tyrosine kinase inhibitor. This phase I study was designed to… 
2015
2015
A phase I study for tolerability, safety, and pharmacokinetics of pyrotinib, a novel irreversible HER2 and EGFR inhibitor, in Chinese patients with HER2+ metastatic breast cancer.
e11596 Background: Pyrotinib is a novel small molecule irreversible pan-tyrosine kinase inhibitor with IC50values of 8.1 nM at… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)